drugset
drugset / Trial / NCT01418339

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01418339 ↗

Phase 3 Completed 135 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.

Timeline

Start
2011-07-27
Primary completion
2013-11-06
Completion
2013-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 52.5 mg Oral
Subject Aripiprazole Other / unclassified 77.5 mg Oral
Subject Aripiprazole Other / unclassified 110 mg Oral

Indications

Tourette syndrome